Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.31 |
| ▸ | ATR | Q13535 | 3/20 | 0.31 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6505740 | 0.89 | PIK3CD (0.37) | RXRARXRBRXRGCYP11B1CYP11B2 | |
| SCHEMBL6502250 | 0.85 | RXRA (0.38) | RXRARXRBRXRGCYP11B1CYP11B2 | |
| SCHEMBL20592982 | 0.77 | RXRA (0.37) | RXRARXRBRXRGCD274CYP4F2 | |
| SCHEMBL6504521 | 0.76 | CYP4F2 (0.35) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL12900076 | 0.76 | RXRA (0.33) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL20592826 | 0.75 | CYP4F2 (0.36) | RXRARXRBRXRGCD274CYP4F2 | |
| SCHEMBL12886311 | 0.75 | MCL1 (0.40) | RXRARXRBRXRGCYP11B1CYP11B2 | |
| SCHEMBL6503097 | 0.75 | PIK3CD (0.36) | RXRARXRBRXRGATR | |
| SCHEMBL6510318 | 0.74 | ABL1 (0.36) | RXRARXRBRXRGCYP11B1CYP11B2 | |
| SCHEMBL12010091 | 0.74 | RXRA (0.40) | RXRARXRBRXRGCD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | PFIZER INC | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090529-A1 | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, CDK4, CDK9 | RXRA 2748/4885RXRB 2441/4885RXRG 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.